AHF Slams Johnson & Johnson for Immoral Profiteering on TB Treatment

20 September 2023 | Wednesday | News

The AIDS Healthcare Foundation (AHF) today strongly condemned pharma giant Johnson & Johnson (J&J) for again putting profits before people’s lives by charging South Africa more than twice what many other countries are paying for the multidrug-resistant tuberculosis (MDR-TB) medicine SIRTURO (bedaquiline) and extending its patent another four years.
Image Source | Public Domain

Image Source | Public Domain

“While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics immediately and sell South Africa bedaquiline at the same cost countries are paying through Stop TB Partnership’s Global Drug Facility. Additionally, J&J must avail the patent for the lifesaving treatment so that generic drug manufacturers can produce the medicine at affordable prices,” said Dr. Kate Ssamula, Country Program Director for AHF South Africa. “We have one of the highest rates of MDR-TB globally, and tuberculosis is the leading cause of death for South Africans, with 56,000 TB deaths in 2021 alone. Johnson & Johnson must be held accountable for its rampant and immoral greed that is keeping us from protecting our citizens.”

AHF has ramped up its tuberculosis advocacy in Africa and worldwide to bring awareness to the global TB response and urge governments everywhere to dedicate sufficient resources to save lives from this preventable and treatable disease.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in